$DEPO (DepoMed Inc.)

$DEPO {{ '2016-02-08T13:53:38+0000' | timeago}} • Announcement

$DEPO said a favorable Markman claim construction ruling by Judge Claire Cecchi of the United States District Court for the District of New Jersey has been issued in the ongoing patent infringement case against the three filers of Abbreviated New Drug Applications with $DEPO prevailing on all disputed claims.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$JNJ {{ '2017-10-17T13:40:49+0000' | timeago}} • Webcast

Only months after promising investors a slew of new blockbuster drugs, $JNJ said it has decided to discontinue clinical trials for two of its drugs. Sirukumab, for the treatment of rheumatoid arthritis, and talacotuzumab, for the treatment of myeloid leukemia, are the drugs that have been discontinued.

$IPXL {{ '2017-10-17T12:55:44+0000' | timeago}} • Announcement

$IPXL has entered into a definitive agreement with Amneal Pharmaceuticals, under which the companies will merge to create the largest generics business in the US. Pursuant to the all-stock transaction, Amneal shareholders will own 75% and Impax shareholders will own 25% of the new company's pro forma shares.

$JNJ {{ '2017-10-17T12:09:28+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q3 2017 Highlights

$UNH {{ '2017-10-17T11:55:37+0000' | timeago}} • Infographic

$UNH UnitedHealth Earnings AlphaGraphics: Q3 2017 Highlights

$JNJ {{ '2017-10-17T11:47:16+0000' | timeago}} • Announcement

$JNJ raised its sales and adjusted earnings guidance for FY17. The New Brunswick, NJ-based healthcare giant now expects sales for the period to be in the range of $76.1 - 76.5Bil, verses the prior guidance of $75.8 - 76.1Bil. Adjusted earnings is anticipated to be $7.25 - $7.30 per share, compared to the prior guidance of $7.12 - $7.22 per share.

$JNJ {{ '2017-10-17T11:36:50+0000' | timeago}} • Announcement

Kicking off the earnings season in healthcare sector, $JNJ reported 10.3% growth in its sales to $19.7Bil in 3Q17. Adjusted earnings also rose double digits to $5.2Bil, or $1.90 per share, driven by strong growth in Pharma unit, as well as Actelion acquisition. On a GAAP basis, earnings fell 12% to $3.8Bil, or $1.37 per share.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$MASI {{ '2017-10-16T21:02:15+0000' | timeago}} • Announcement

$MASI announced that the bankruptcy court in San Diego has issued final judgment holding that Sotera Wireless Employees misappropriated Masimo trade secrets. The misappropriation stems from two former Masimo employees, James Welch and David Hunt, copying thousands of confidential Masimo documents and using Masimo’s trade secrets to benefit Sotera.

$JNJ {{ '2017-10-16T14:43:30+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech Inc. has received FDA approval for an expanded indication for STELARA for the treatment of adolescents with plaque psoriasis.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$VRX {{ '2017-10-10T14:50:38+0000' | timeago}} • Infographic

$VRX's progress towards paying down a huge debt of $5Bil before Feb 2018.

$DEPO {{ '2017-10-10T13:44:58+0000' | timeago}} • Announcement

$DEPO said that as a result of the disruption to manufacturing operations in Puerto Rico due to Hurricane Maria, it is experiencing temporary delays in packaging and delivery of certain dosage strengths of NUCYNTA ER at the facility in Puerto Rico. Consequently, $DEPO expects its 4Q17 product revenue to be negatively impacted by less than $10MM.

$JNJ {{ '2017-10-05T13:58:49+0000' | timeago}} • Announcement

Animas Corp., a $JNJ Diabetes Care Companies, plans to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected $MDT as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers.

$MYL {{ '2017-10-04T11:50:31+0000' | timeago}} • Announcement

Pharma company $MYL said it received FDA approval for its Abbreviated New Drug Applications for two variants of Glatiramer Acetate injection, a generic version of $TEVA’s Copaxone - indicated for the treatment of multiple sclerosis. Mylan expects to start shipping of the medicines soon, which will be available by prescription only.

$JNJ {{ '2017-10-02T21:24:15+0000' | timeago}} • Announcement

$JNJ completed divestiture of its Codman Neurosurgery business to $IART for about $1.045Bil. The Codman Neurosurgery business offers a portfolio of devices focused on hydrocephalus management, neuro intensive care and cranial surgery, and generated net revenues of about $371.5MM in 2016.

$MYL {{ '2017-10-02T17:33:18+0000' | timeago}} • Announcement

$MYL announced the U.S. launch of Caspofungin Acetate for Injection, one of the first generic version of $MRK's Cancidas. $MYL received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for this antifungal which has multiple indications.

$AGN {{ '2017-10-02T17:04:07+0000' | timeago}} • Announcement

FDA accepts to do a priority review of $AGN's antibiotic drug Avycaz. The supplemental New Drug Application (sNDA) filed by Allergan seeks to expand the usage of Avycaz for the treatment of patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. The FDA is expected to take action on the filing in 1Q18.

$MYL {{ '2017-09-29T21:46:47+0000' | timeago}} • Announcement

$MYL announced the US launch of Imatinib Mesylate Tablets, a generic version of Novartis's Gleevec Tablets. $MYL received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which has multiple indications, including for several blood cancers.

Recent Transcripts

CLSN (Celsion Corporation)
Tuesday, August 15 2017 - 3:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
IPXL (Impax Laboratories Inc.)
Wednesday, August 9 2017 - 12:30pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 3:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
DEPO (DepoMed Inc.)
Monday, August 7 2017 - 8:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
INSM (Insmed Incorporated)
Thursday, August 3 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, August 3 2017 - 11:30am
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, July 27 2017 - 12:30pm

AlphaGraphics you may like